Research Desk Line-up: Applied Genetic Technologies Post Earnings Coverage
LONDON, UK / ACCESSWIRE / September 25, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Aviragen Therapeutics, Inc. (NASDAQ: AVIR), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=AVIR, following the Company's reporting of its financial results on August 31, 2017, for the fourth quarter fiscal 2017 (Q4 FY17) and full year 2017 (FY17). The Atlanta, Georgia-based Company's net loss narrowed during the reported quarter. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:
Get more of our free earnings reports coverage from other constituents of the Biotechnology industry. Pro-TD has currently selected Applied Genetic Technologies Corporation (NASDAQ: AGTC) for due-diligence and potential coverage as the Company announced on August 08, 2017, its financial results for the quarter and fiscal year which ended on June 30, 2017. Register for a free membership today, and be among the early birds that get access to our report on Applied Genetic Technologies when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on AVIR; also brushing on AGTC. With the links below you can directly download the report of your stock of interest free of charge at:
In Q4 FY17, Aviragen's total revenue was $0.1 million compared to $0.6 million in Q4 FY16. The Company's revenues of Q4 FY16 consisted of royalties from Relenza amounting to $0.4 million and $0.2 million in non-cash royalty revenue related to certain royalty rights sold to HealthCare Royalty Partners III, L.P. The Company posted net loss of $5.9 million, or $0.16 loss per basic and diluted share, in Q4 FY17 compared to net loss of $7.1 million, or $0.18 loss per basic and diluted share, in the previous year's same period.
The pharmaceutical Company reported total revenue of $8.9 million in FY17 compared to $9.3 million in FY16. The decline in total revenues during the period is due to fall in royalty revenues from Relenza. Additionally, the Company's net loss widened to $29.4 million, or $0.76 loss per basic and diluted share, during FY17 from $25.4 million, or $0.66 loss per basic and diluted share, in FY16.
During the reported quarter, the Company spent $3.7 million on research and development, which came in lower than the $6.0 million incurred in Q4 FY16, primarily due to reduced clinical trial activity as two of the three Phase-2 clinical trials came to a close. Meanwhile, the Company's general and administrative expense increased to $2.0 million during Q4 FY17 from $1.2 million in Q4 FY16, due mostly to higher legal and professional fees. The Company posted loss from operations of $5.6 million in Q4 FY17 compared to loss from operations of $6.7 million in Q4 FY17.
Cash Flow & Balance Sheet
During the year ended June 30, 2017, the Company's net cash used by its operating activities was $30.0 million compared to net cash used by operating activities of $14.1 million in the year-ago same period. The Company's cash balance declined to $17.7 million as on June 30, 2017, from $49.7 million at the close of books on June 30, 2016. Furthermore, the Company has an accumulated deficit of $163.8 million as on June 30, 2017, compared to $134.3 million as on June 30, 2016.
On Friday, September 22, 2017, the stock closed the trading session at $0.65, climbing 4.00% from its previous closing price of $0.63. A total volume of 62.26 thousand shares have exchanged hands. Aviragen Therapeutics' stock price surged 11.88% in the last one month and 12.20% in the past three months. The stock currently has a market cap of $25.12 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily